title: Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
abstract: Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with an outpatient schedule: cisplatin (100 mg/m2) day 1 and an 8-hour infusion of 5-fluorouracil (1000 mg/m2) on days 1-4 every 28 days. Twenty-eight patients were evaluable for response and toxicity: there were 5 complete responses (17.8%), 12 partial responses (42.8%), 6 stable disease (21.6%) and 5 progressions (17.8%). Patients with good performance status had a better response; patients who received prior chemotherapy had less positive responses. Median remission duration was 30+ weeks in patients who had a complete response, 25+ weeks in patients with a partial response. Median overall survival was 28+ weeks: 36+ weeks for responders and 14 weeks for non-responders. The major toxic effect was nausea/vomiting, while myelosuppression and stomatitis were less frequent and never severe.
authors.affiliation: Clinica Medica II, Università di Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Airoldi
authors.forename: F
authors.initials: F
authors.lastname: Pedani
authors.forename: V
authors.initials: V
authors.lastname: Brando
authors.forename: C
authors.initials: C
authors.lastname: Giordano
authors.forename: P
authors.initials: P
authors.lastname: Gabriele
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010045:Outpatients
chemical_list: D002945:Cisplatin; D005472:Fluorouracil